■丙泊酚和依托咪酯是手术镇静中最常用的镇静剂,每个人都有自己的优点和缺点。然而,关于这两种药物混合物的最佳比例仍然存在相当大的争议,保证进一步调查。因此,本研究旨在探讨胃镜检查中丙泊酚和依托咪酯联合使用的最佳比例。
■这项研究是一项前瞻性研究,双盲,随机对照临床试验。选择2019年7月至2022年12月的162例患者,采用随机数字表法将其分为3组:(1)P组(丙泊酚);(2)EP1组(依托咪酯5mL+丙泊酚10mL);(3)EP2组(依托咪酯10mL+10mL),每组54名患者。药物,包括50μg/kg地佐辛的镇静前剂量,然后是镇静剂,当病人的睫毛反射消失时停止,表明足够的镇静。平均动脉压(MAP),心率(HR),和麻醉前(T1)进行的外周血氧饱和度(SpO2)测量,服用镇静剂后立即(T2),确定立即胃镜插入(T3)和立即恢复(T4)。额外,同时记录围手术期相关结局和不良事件.
■与P和EP1组相比,EP2组在T2时表现出更高的MAP(p<0.05)。计算的MAP下降显示P的值为19.1、18.8和13.8%,EP1和EP2组分别在T2。不良事件:EP2组低血压发生率(11.1%)明显低于丙泊酚组(50%)和EP1组(31.5%)。关于注射疼痛,与P组和EP1组相比,EP2组也显示出显著降低(p<0.05)。
■使用10mL依托咪酯和10mL异丙酚的混合物(比例为1:1)与地佐辛联合用于无痛胃镜检查证明了血液动力学稳定性,不良反应发生率低。
■https://www.chictr.org.cn/showproj.html?proj=39874。
UNASSIGNED: Propofol and etomidate are the most commonly used sedative agents in procedural sedation, each with its own advantages and disadvantages. However, there remains considerable controversy regarding the optimal ratio for the mixture of these two drugs, warranting further investigation. Therefore, this study aims to investigate the optimal ratio for combining propofol and etomidate during
gastroscopy.
UNASSIGNED: This study is a prospective, double-blinded, randomized controlled clinical trial. One hundred and sixty-two patients from July 2019 to December 2022 were evenly classified into three groups using a random number table as follows: (1) P group (propofol); (2) EP1 group (5 mL etomidate +10 mL propofol); (3) EP2 group (10 mL etomidate +10 mL), 54 patients per group. The medications, including a pre-sedation dose of 50 μg/kg dezocine followed by sedatives, ceasing when the patient\'s eyelash reflex vanished, indicating adequate sedation. Mean arterial pressure (MAP), heart rate (HR), and peripheral oxygen saturation (SpO2) measurements taken before anesthesia (T1), immediately after the administration of sedatives (T2), immediately gastroscopic insertion (T3) and immediately recovery (T4) were determined. Additional, perioperative related outcomes and adverse events were also recorded.
UNASSIGNED: The EP2 group exhibited a higher MAP at T2 compared to the P and EP1 groups (p < 0.05). Calculated decreases in MAP revealed values of 19.1, 18.8, and 13.8% for the P, EP1, and EP2 groups at T2, respectively. Adverse events: Group EP2 exhibited a significantly lower hypotension incidence (11.1%) compared to the Propofol group (50%) and EP1 (31.5%). Concerning injection pain, Group EP2 also showing a significant decrease in comparison to P and EP1 groups (p < 0.05).
UNASSIGNED: The use of a mixture of 10 mL etomidate and 10 mL propofol (at a 1:1 ratio) combined with dezocine for painless
gastroscopy demonstrates hemodynamic stability, a low incidence of adverse reactions.
UNASSIGNED: https://www.chictr.org.cn/showproj.html?proj=39874.